Literature DB >> 26898841

"Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances".

A Arjona-Sánchez1, A Cadenas-Febres2, J Cabrera-Bermon2, F C Muñoz-Casares3, A Casado-Adam2, J M Sánchez-Hidalgo3, M López-Andreu4, J Briceño-Delgado3, S Rufián-Peña3.   

Abstract

BACKGROUND: The acute renal dysfunction (ARD) is a common complication in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Our aim is evaluate the ARD post-HIPEC procedures using the RIFLE and AKIN criteria. Evaluate the risk factors and analyze ARD's impact on postoperative course.
METHODS: From 2011 to 2014, in a retrospective way using a prospective database were operated by HIPEC procedure. The ARD was analyzed by RIFLE and AKIN criteria. The perioperative features were analyzed and a multivariate analysis was performed to define the risk factors to develop the ARD.
RESULTS: 141 patients were treated and analyzed. The ARD was detected in 30.5% (Injury 18.4% and Failure 12.1%) when RIFLE criteria were applied. The multivariate analysis detected that decrease of pH during HIPEC [OR = 29.39 (5.09-169.76)], PCI [OR = 1.07 (1.01-1.15)] and ureteral catheters [OR = 12.71 (1.44-111.85)] were associated to the development of acute renal injury (ARI) post-HIPEC. Decrease of Na during HIPEC [OR = 1.15 (1.01-1.30)], intraoperative inotrope use [OR = 3.83 (1.12-13.09)] and PCI [OR = 1.06 (1.0-1.14)] were associated to acute renal failure (ARF) post-HIPEC. The ARD was related to a higher length of stay hospital (17.2 ± 11 vs. 13.8 ± 8 days) (p = 0.05) but no impact in early survival was observed in ARD group.
CONCLUSIONS: The widespread use of RIFLE criteria for ARD would have major benefits in terms of accurately diagnosing patients undergone HIPEC procedures. The ARD has a detrimental impact in length of stay hospital. The knowledge of risk factors helps us to prevent the ARD post-HIPEC by means of an aggressive and multidisciplinary perioperative management.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute renal failure; HIPEC; Peritoneal carcinomatosis; RIFLE

Mesh:

Year:  2016        PMID: 26898841     DOI: 10.1016/j.ejso.2015.12.016

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  8 in total

1.  Association of intraoperative gross hematuria with acute kidney injury after cytoreductive surgery.

Authors:  Yumi Mitani; Yohei Arai; Yoshimasa Gohda; Hideaki Yano; Isao Kondo; Emi Sakamoto; Daisuke Katagiri; Fumihiko Hinoshita
Journal:  Pleura Peritoneum       Date:  2022-02-18

2.  Routine prophylactic ureteral stenting before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Safety and usefulness from a single-center experience.

Authors:  Paola Fugazzola; Federico Coccolini; Matteo Tomasoni; Enrico Cicuttin; Maria Grazia Sibilla; Francesca Gubbiotti; Andrea Lippi; Mario Improta; Giulia Montori; Marco Ceresoli; Michele Pisano; Luca Ansaloni
Journal:  Turk J Urol       Date:  2019-09-01

3.  HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma.

Authors:  A Arjona-Sánchez; P Barrios; E Boldo-Roda; B Camps; J Carrasco-Campos; V Concepción Martín; A García-Fadrique; A Gutiérrez-Calvo; R Morales; G Ortega-Pérez; E Pérez-Viejo; A Prada-Villaverde; J Torres-Melero; E Vicente; P Villarejo-Campos; J M Sánchez-Hidalgo; A Casado-Adam; Ruben García-Martin; Manuel Medina; T Caro; C Villar; Enrique Aranda; M T Cano-Osuna; C Díaz-López; E Torres-Tordera; F J Briceño-Delgado; S Rufián-Peña
Journal:  BMC Cancer       Date:  2018-02-13       Impact factor: 4.430

4.  Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Matilde Zaballos; Mercedes Power; María Iluminada Canal-Alonso; María Ángeles González-Nicolás; Wenceslao Vasquez-Jimenez; Pablo Lozano-Lominchar; Pilar Cabrerizo-Torrente; Natividad Palencia-García; Susana Gago-Quiroga; María Dolores Ginel-Feito; Consuelo Jiménez; Alberto Lázaro; Luis González-Bayón
Journal:  Int J Mol Sci       Date:  2021-01-27       Impact factor: 5.923

Review 5.  Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.

Authors:  Pei-Qi Lim; I-Hung Han; Kok-Min Seow; Kuo-Hu Chen
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

6.  The Role of Intraperitoneal Intraoperative Chemotherapy with Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis from Ovarian Cancer-Hyperthermia versus Normothermia: A Randomized Controlled Trial.

Authors:  Angela Casado-Adam; Lidia Rodriguez-Ortiz; Sebastian Rufian-Peña; Cristobal Muñoz-Casares; Teresa Caro-Cuenca; Rosa Ortega-Salas; Maria Auxiliadora Fernandez-Peralbo; Maria Dolores Luque-de-Castro; Juan M Sanchez-Hidalgo; Cesar Hervas-Martinez; Antonio Romero-Ruiz; Javier Briceño; Álvaro Arjona-Sánchez
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

7.  The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer.

Authors:  Kate Glennon; Karen Mulligan; Kirsten Carpenter; Ruth Mooney; Jurgen Mulsow; Orla McCormack; William Boyd; Tom Walsh; Ruaidhri McVey; Claire Thompson; Brid Ryan; Katie Padfield; Patrick Murray; Donal J Brennan
Journal:  Gynecol Oncol Rep       Date:  2021-05-26

8.  HIPEC-Induced Acute Kidney Injury: A Retrospective Clinical Study and Preclinical Model.

Authors:  Lukas F Liesenfeld; Benedikt Wagner; H Christian Hillebrecht; Maik Brune; Christoph Eckert; Johannes Klose; Thomas Schmidt; Markus W Büchler; Martin Schneider
Journal:  Ann Surg Oncol       Date:  2021-07-14       Impact factor: 5.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.